Back to search

National and Kapodistrian University of Athens

Ο ρόλος των μοριακών δεικτών DEK, SURVIVIN, P33ING1, MMP-2, C-ERBB-2 στην πρόγνωση του ουροθηλιακού καρκινώματος της ουροδόχου κύστεως

Abstract

dc:description

Urothelial bladder cancer is the second most common genitourinary tumor and constitutes an important cause of morbidity and mortality. It presents a meaningful heterogeneity in biological behaviour that is not completely understood. It is well known that two morphologically similar tumors presenting in any assigned stage may behave in different fashions, a fact that seriously impedes the potential to accurately predict the clinical outcome in a given case. The ability to designate those superficial tumors with an adverse disease outcome and those unlikely to become invasive or clinically threatening, would be of great clinical benefit. Superficial tumors that maintain a more malignant phenotype may be better treated with early aggressive therapy. In our study archival tumor tissue from 80 patients with urothelial carcinoma were analysed by immunohistochemistry. The aim of this study was to investigate the expression pattern of survivin, c-erbB-2, DEK, MMP-2 and P33ING1 in order to determine their potential prognostic significance. Since its discovery in 1997, survivin has garnered significant interest due to its putative role as an inhibitor of apoptosis. Few studies have investigated the immunohistochemical status of survivin in urothelial bladder carcinoma. The subcellular localization of survivin (nuclear, cytoplasmic) and its differential predictive value is a parameter that previous studies have almost ignored. In our study nuclear and cytoplasmic positive scores of 61.25% (49/80) and 22.5% (18/80), respectively were found. Nuclear positive staining correlated strongly with increased grade (p=0.001), stage (p= 0.039) and the probability of tumor recurrence (p=0.029). No relationship was found between the cytoplasmic survivin level and the clinicopathological parameters. Nuclear expression was identified as a significant independent predictor of relapse-free survival (p=0.016). The HER2/neu protein was overexpressed in 41 of 80 patients (51,25%), demonstrating an increase in the expression rate corresponding to the advancement of tumor grade (p=0,0001) and tumor stage (p=0,032). Kaplan Meier analyses showed that positive membranous expression of HER2/neu was not associated with an increased probability of tumor recurrence (p=0,362). Contrarily, the HER2 scores correlated strongly with specific survival probability (p=0,002) and overall survival (p=0,025) analyzing all patients. The multivariate analysis revealed that only stage was an independent predictor of specific survival. (p=0,016). The HER2 expression was an independent predictor of specific survival with borderline statistical significance (p=0,08). High DEK protein expression was found in 51/80 tumors and was significantly associated with tumor invasiveness and tumor grade (p=0.016 and p=0.001, respectively). Kaplan Meier analyses showed that positive nuclear expression of DEK was associated with an increased probability of tumor recurrence with borderline statistical significance (p=0.055). DEK scores did not correlated with overall survival (p=0.429) and specific survival (p=0.323) analyzing all patients. Only tumor stage correlated strongly with overall survival (p=0.002) and specific survival (p=0.0001). Positive MMP-2 expression was found in 35/80 tumors. The staining was granular and was localized in cytoplasm. No relationship was found between the cytoplasmic MMP-2 level and the clinicopathological parameters. MMP-2 scores did not correlated with disease-free, overall or specific survival. Positive P33ING1 expression was found in 19/56 tumors. No relationship was found between the nuclear P33ING1 expression and the clinicopathological variables. We propose that survivin is a potential molecular marker for prediction of bladder cancer’s behavior. Our data corroborate the findings of other studies that HER-2 overexpression is high in patients with advanced bladder cancer and influences the outcome of these patients, thereby suggesting that HER-2 is a potential target for treatment of this cancer. Our findings indicate that DEK may contribute to the development of advanced bladder cancer. These conclusions have to receive further validation in larger prospective series.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2010

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Σκάγιας, Λάζαρος
  • Skagias, Lazaros

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/31555

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Σκάγιας, Λάζαρος; Skagias, Lazaros. Ο ρόλος των μοριακών δεικτών DEK, SURVIVIN, P33ING1, MMP-2, C-ERBB-2 στην πρόγνωση του ουροθηλιακού καρκινώματος της ουροδόχου κύστεως. National and Kapodistrian University of Athens, 2010. http://hdl.handle.net/10442/hedi/31555